Adial Pharmaceuticals, Inc. (ADIL) Stock Price & Analysis

Adial Pharmaceuticals, Inc. (ADIL) fell 4.05% to USD 6.83 as of September 8, 2026 at 16:19 UTC, according to Nexqual real-time market data.

ADIL last closed at USD 6.83; the session ranged USD 6.55–7.2 on volume of 20,111 shares. Market capitalization is —, with a 52-week range of USD 1.31–10.75 (NCM). Source: Nexqual, September 8, 2026 at 16:19 UTC.

Key Statistics (as of September 8, 2026 at 16:19 UTC)

Technical Analysis (ADIL)

Nexqual's technical model rates ADIL "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of September 8, 2026 at 16:19 UTC.

From Adial Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• Three patent and patent application families are included in the UVA LVG License, with patents issued in over 40 countries, including, without limitation, in the U.S., Europe and Eurasia.
• The license agreement, as amended on October 21, 2013, and further amended on May 18, 2016, March 27, 2017, August 15, 2017, December 14, 2017, December 18, 2018, December 31, 2019, and October 21, 2024 sets forth specific diligence milestones completion deadlines including using commercially reasonable efforts to submit an NDA with the FDA for a Licensed Product by March 31, 2028 and commence commercialization of an FDA approved Licensed Product by March 31, 2029.
• Ondansetron, the active pharmaceutical ingredient ("API") of AD04 was granted FDA approval as Zofran ® for the treatment of post-operative and post-chemotherapy nausea and emesis in January 1991 and is now commercially available in generic form at doses from more than 12 times the AD04 dose to over 70 times the AD04 dose with the highest doses being administered intravenously ("i.v."), which provides almost twice the drug exposure levels as oral dosing.
• Our approach, if approved by FDA, may allow for social drinking to continue and is aimed at reducing the dangerous, heavy drinking.

Partnerships

• Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop AD04.   Recent Developments   Collaboration Framework   On March 3, 2026, we entered into a collaboration framework agreement with a strategic partner, Molteni Farmaceutici ("Molteni"), for a proposed exclusive partnership covering the commercialization of AD04 in Europe.
• Our licensed therapeutic agent was the product candidate used in the ONWARD Phase 3 clinical trial of 302 patients as well as a University of Virginia investigator sponsored Phase 2b clinical trial of 283 patients.   9     In January 2011, we entered into an exclusive, worldwide license agreement with UVA LVG for rights to make, use or sell licensed products in the United States based upon the patents and patent applications made and held by UVA LVG (the "UVA LVG License").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 16:19 UTC. This page is informational and not investment advice.